Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.50 -2.0%	$1.61	$0.99 ▼ $6.14	$137.19M	2.74	1.54 million shs	790,962 shs
FSDDF FSD Pharma	$18.09 +0.2%	$22.54	$3.43 ▼ $68.66	$137.08M	N/A	11,100 shs	78,057 shs
MOLN Molecular Partners	$3.81 -2.0%	$3.69	$3.36 ▼ $7.60	$153.99M	1.1	6,586 shs	6,597 shs
PVCT Provectus Biopharmaceuticals	$0.08 -5.9%	$0.08	$0.07 ▼ $0.15	$35.60M	0.57	188,023 shs	53,260 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-3.77%	-5.56%	-7.83%	-18.18%	-74.37%
FSDDF FSD Pharma	0.00%	-19.44%	-28.09%	+56.31%	+329.57%
MOLN Molecular Partners	-7.82%	+8.06%	-2.97%	-2.87%	-38.25%
PVCT Provectus Biopharmaceuticals	+5.88%	+12.22%	+20.00%	-0.99%	-28.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.843 of 5 stars	3.5	4.0	0.0	0.0	2.7	0.8	0.6
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	2.0653 of 5 stars	3.8	2.0	0.0	0.0	2.2	0.0	0.6
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	861.90% Upside
FSDDF FSD Pharma	0.00	N/A	N/A	N/A
MOLN Molecular Partners	3.50	Strong Buy	$12.00	214.63% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PVCT, CABA, MOLN, and FSDDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
FSDDF FSD Pharma	$70K	1,958.35	N/A	N/A	N/A	∞
MOLN Molecular Partners	$681K	226.12	N/A	N/A	$3.99 per share	0.96
PVCT Provectus Biopharmaceuticals	$620K	57.42	N/A	N/A	($0.01) per share	-8.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	11/13/2025 (Estimated)
FSDDF FSD Pharma	-$17.52M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	-$61.39M	-$2.08	N/A	N/A	N/A	N/A	-48.58%	-43.74%	10/30/2025 (Estimated)
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-1,374.19%	N/A	-792.87%	11/10/2025 (Estimated)

Latest PVCT, CABA, MOLN, and FSDDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/25/2025	H1 2025	MOLN Molecular Partners	-$0.53	-$0.67	-$0.14	-$0.67	N/A	N/A
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
FSDDF FSD Pharma	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	4.78	4.78
FSDDF FSD Pharma	N/A	1.81	1.60
MOLN Molecular Partners	N/A	15.28	15.28
PVCT Provectus Biopharmaceuticals	N/A	0.09	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
FSDDF FSD Pharma	0.43%
MOLN Molecular Partners	26.55%
PVCT Provectus Biopharmaceuticals	0.05%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
FSDDF FSD Pharma	N/A
MOLN Molecular Partners	5.93%
PVCT Provectus Biopharmaceuticals	12.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	91.46 million	81.18 million	Optionable
FSDDF FSD Pharma	10	7.58 million	N/A	Not Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	366.48 million	Not Optionable

PVCT, CABA, MOLN, and FSDDF Headlines

Recent News About These Companies

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - Morningstar

June 27, 2025 | morningstar.comM

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

June 26, 2025 | globenewswire.com

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

June 9, 2025 | globenewswire.com

Croatia's Provectus Capital Partners opens office in Romania

April 24, 2025 | seenews.comS

Provectus announces $3M seed financing round for VisiRose

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | globenewswire.com

Provectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmology

December 13, 2024 | pharmabiz.comP

Provectus announces the launch of VisiRose

December 12, 2024 | markets.businessinsider.com

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

December 10, 2024 | miamiherald.comM

Provectus Pharmaceuticals Aligns Leadership with Equity Grants

December 6, 2024 | markets.businessinsider.com

Provectus Pharmaceuticals to Reveal Key 2024 Updates

November 15, 2024 | markets.businessinsider.com

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

October 24, 2024 | manilatimes.netM

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

October 10, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

May 21, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

May 14, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

April 18, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

April 16, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium

March 27, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVCT, CABA, MOLN, and FSDDF Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.50 -0.03 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 +0.03 (+2.00%)

As of 05:54 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

FSD Pharma OTCMKTS:FSDDF

$18.09 +0.04 (+0.19%)

As of 08/22/2025

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Molecular Partners NASDAQ:MOLN

$3.81 -0.08 (-1.95%)

Closing price 03:58 PM Eastern

Extended Trading

$3.82 +0.00 (+0.03%)

As of 05:56 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.08 -0.01 (-5.89%)

As of 03:57 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time